News & Updates
Filter by Specialty:
Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma
The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.
Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma
25 Jan 2022
Investigative drug for ulcerative colitis passes muster in early trial
The orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α (HIF-1α) GB004 appears to improve disease activity in patients with ulcerative colitis, with the drug being well-tolerated, according to the results of a phase Ib trial.
Investigative drug for ulcerative colitis passes muster in early trial
25 Jan 2022
Which AECOPD patients are likely to test positive for flu?
In patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), higher body temperature and heart rate, along with low white cell counts, are strong predictors of testing positive for influenza, according to a recent Singapore study.
